Panama’s Law 419/2024: What the High Standard Country Pathway Means for Your Market Access Strategy
2024–2026 · Pharmaceuticals, Medical Devices & Personal Care · Panama
Panama’s regulatory reform of the last two years is not incremental. Law 419/2024 and its implementing decree changed the baseline assumptions for companies evaluating market entry and, for those already registered, reshaped the competitive landscape.
Understanding what the reform actually covers, and what it still requires, is the difference between moving fast and moving wrong.
What Law 419/2024 Established
Enacted with an implementation date of February 1, 2024, Law 419/2024 introduced the High Standard Country (HSC) recognition pathway. Products approved by the FDA, EMA, Health Canada, and other recognized authorities became eligible for expedited review in Panama. The law also introduced seven new contractor selection models aimed at procurement transparency.
The scope covers medicines, medical devices, diagnostics, cosmetics, and personal care products.
Executive Decree 2/2025: The Expansion
On January 7, 2025, Executive Decree 2/2025 further extended the reform. HSC recognition was expanded to all WHO-listed regulatory authorities, not just the original short list. The decree also eliminated the requirement for local laboratory analysis for products already approved by those authorities, and established streamlined documentation requirements for qualified products.
The practical effect: automatic recognition for products registered in WHO-listed countries, with a simplified submission process.
The reform didn’t just open a faster lane. It redefined who qualifies for it and on what terms.
What the Pathway Requires
Speed does not mean fewer requirements. Companies pursuing the HSC pathway must still provide a valid approval from a recognized authority, documentation in CTD format, a comprehensive risk management plan, Spanish-language labeling, and a designated local representative. None of these are optional.
The reform accelerates the review; it does not eliminate the regulatory infrastructure a company needs to operate in Panama.
The Competitive Dimension
The reported reduction in approval timelines for qualified products is substantial. So is the reduction in regulatory compliance costs. For companies with HSC approvals in hand, the pathway represents a first-mover opportunity in a market that has historically moved slowly.
For companies that don’t yet have those approvals, Panama’s reform is still relevant; it shapes the strategic sequencing of where to enter first and how to structure a regional registration plan.
What to Watch
Panama’s reform also included procurement changes (seven new contractor selection models) that affect how healthcare products enter the public procurement system. Companies operating or planning to operate in the institutional channel should understand how these interact with the registration pathway.
Rebexa monitors regulatory developments across 16+ markets. If you have questions about how Law 419/2024 or Executive Decree 2/2025 affects your product portfolio in Panama, contact us.